The timing of adoption of positron emission tomography: A real options approach

Health Care Management Science

Volumn 12, Issue 3, 2009, Pages 217-227

  Pertile, Paolo ^a   Torri, Emanuele ^b   Flor, Luciano ^c   Tardivo, Stefano ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Forest and Wildlife Service   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Investment timing; Positron emission tomography; Real options; Technology adoption

Indexed keywords

ACCOUNTING; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; HOSPITAL MANAGEMENT; HUMAN; POSITRON EMISSION TOMOGRAPHY; STATISTICAL MODEL;

ACCOUNTING; COST-BENEFIT ANALYSIS; HOSPITAL ADMINISTRATION; HUMANS; MODELS, ECONOMETRIC; POSITRON-EMISSION TOMOGRAPHY;

EID: 70349317478     PISSN: 13869620     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10729-008-9085-4     Document Type: Article

References (38)

1. Dixit A, Pindyck RS (1995) The options approach to capital investment. Harvard Bus Rev 73(3):105-115
2. Dixit A, Pindyck RS (1994) Investment under uncertainty. Princeton University Press, Princeton
3. Schwartz ES, Trigeorgis L (2001) Real options and investment under uncertainty: Classical readings and recent contributions. MIT, Cambridge
4. Palmer S, Smith PC (2000) Incorporating option values into the economic evaluation of healthcare technologies. J Health Econ 19(5):755-766
5. Abrams HL, McNeil BJ (1978) Medical implications of computed tomography ("CAT scanning"). Part I. New Engl J Med 298(5):255-261
6. Batista RN (1989) Innovation and diffusion of health related technologies. A conceptual framework. Int J Technol Assess Health Care 5(2):227-248
7. Gazelle GS, McMahon PM, Siebert U, Beinfeld MT (2002) Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. Radiology 235(2):361-370
8. Bodenheimer T (2005) High and rising health care costs. Part 2: Technologic innovation. Ann Intern Med 142(11):932-937
9. Lasserre P, Moatti J, Soubeyran A (2006) Early initiation of highly active antiretroviral therapies for AIDS: Dynamic choice with endogenous and exogenous learning. J Health Econ 25(3):579-598
10. Driffield T, Smith PC (2007) A real options approach to watchful waiting: Theory and an illustration. Med Decis Mak 27(2):178-188
11. Institute for Clinical Evalutative Sciences (2004) Health technology assessment of positron emission tomography (PET) in oncology-a systematic review. Institute for Clinical Evalutative Sciences, Toronto
12. Juweid ME, Cheson BD (2006) Positron emission tomography and assessment of cancer therapy. N Engl J Med 354(5):496-507
13. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, Altman H, Keidar Z, Israel O (2003) Clinical performance of PET/CT in evaluation of cancer: Additional value for diagnostic imaging and patient management. J Nucl Med 44(8):1200-1209
14. Groves AM, Cullum I, Syed R, Nagabushan N, Kayani I, Pakzad F, Ell PJ (2005) How often do patients undergo repeat PET or PET/CT examinations? Experience from a UK institution. Nucl Med Commun 26(2):137-139
15. Bedford M, Maisey MN (2004) Requirements for clinical PET: Comparisons with Europe. Eur J Nucl Med Mol Imaging 31(6):208-221
16. Cleemput I, Camberlin C, van den Bruel A, Ramaekers D (2008) Methodology for calculating a country's need for positron emission tomography scanners. Int J Technol Assess Health Care 24(1):20-24
17. Dahlbom M, Hoffman EJ, Hoh CK, Schiepers C, Rosenqvist G, Hawkins RA, Phelps ME (1992) Evaluation of a positron emission tomography (PET) scanner for whole body imaging. J Nucl Med 33:1191-1199
18. Bradbury I, Facey K, Laking G, Sharp P (2003) Investing in new technology: The PET experience. Br J Cancer 89(2):224-227
19. Rodríguez Garrido M, Asensio del Barrio C (2004) PET-TAC: indicaciones, revisión sistemática y meta-análisis. IPE-04/41. Agencias de Evaluación de Tecnologias Sanitaria, Madrid, Spain. In Spanish. http://www.isciii.es. Accessed 14 Jan 2008
20. Schoder H, Erdi YE, Larson SM, Yeung HW (2003) PET/CT: A new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging 30(10):1419-1437
21. Townsend DW, Carney JP, Yap JT, Hall NC (2004) PET/CT today and tomorrow. J Nucl Med 45(Suppl 1):4S-14S
22. Facey K, Bradbury I, Laking G, Payne E (2007) Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 11(44):1-288
23. Perkins AC, Gordon I, Read J, Ellis B, Professional Standards and Education Committee of the British Nuclear Medicine Society, Allen R, Clarke SE, Garner C, Hilson AJ, Frank JW, McCool D, Nicol A, Prescott MC, Ryan PJ, Shields RA, Tindale WB (2006) Training of staff for the delivery of PET/CT services in the UK. Nucl Med Commun 27(12):1005-1010
24. Department of Health (2004) A framework for the development of positron emission tomography (PET) services in England. Department of Health, London
25. Morland B (2004) Positron emission tomography (PET)-diagnostic and clinical use. INAHTA brief issue 2004/80. The Norwegian Centre for Health Technology Assessment (SMM), Oslo, Norway
26. Maisey MN (2002) Overview of clinical PET. Br J Radiol 75(Spec No):S1-S5
27. Agency for Health Care Research and Quality (AHCRQ) (2004) Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular). US Department of Health and Human Services, Rockville
28. Brandbury I, Bonell E, Boynton J, Cummins E, Facey K, Iqbal K, Laking G, McDonald C, Parpia T, Sharp P, Single A, Walker A (2002) Positron emission tomography (PET) imaging in cancer management. Health Technology Assessment Report 2. Health Technology Board for Scotland, Glasgow
29. Williams R, Wright J (1999) Epidemiological issues in health needs assessments. BMJ 316(7141):1379-1382
30. Donahue JX (2003) Certificate of need process: An assessment of the need for PET. Med Health R I 86(5):147-149
31. National Institute for Clinical Excellence (NICE) (2005) Health needs assessment: A practical guide. Health Development Agency, London
32. Torbica A, Fattore G (2005) The essential levels of care in Italy: when being explicit serves the devolution of powers. Eur J Health Econ 6(Suppl 1):46-52
33. Agenzia Regionale Socio-Sanitaria del Veneto (2007) Tomografia ad emissione di positroni (PET): valutazione del fabbisogno e piano di investimento per la regione veneto. Quaderno n. 3. Venezia, Italy. In Italian. https://www.arssveneto.it. Accessed 14 Jan 2008
34. Hertz D, Thomas H (1983) Risk analysis and its applications. Wiley, Chichester
35. Grande E, Inghelmann R, Francisci S, Verdecchia A, Micheli A, Capocaccia R, De Angelis R (2006) Estimating regional cancer burden in countries with partial registration coverage: An application to all malignant neoplasms in Italy over the period 1970-2010. Eur J Cancer 42(18):3236-3245
36. Liberati A, Longo G, Ballini L, De Palma R (2007) FDG-PET in oncologia. Criteri per un uso appropriato. Dossier n. 157. Agenzia Sanitaria Regionale, Bologna, Italy. In Italian. http://asr.regione.emilia-romagna.it. Accessed 14 Jan 2008
37. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42(5 Suppl):1S-93S
38. Claxton K (1999) The irrelevance of inference: A decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 18(3):341-364